NASDAQ:NBIX

Neurocrine Biosciences Stock Forecast, Price & News

$96.58
+1.58 (+1.66 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$94.56
Now: $96.58
$96.92
50-Day Range
$87.57
MA: $96.07
$109.51
52-Week Range
$86.02
Now: $96.58
$136.26
Volume601,682 shs
Average Volume1.21 million shs
Market Capitalization$9.13 billion
P/E Ratio103.85
Dividend YieldN/A
Beta1.01
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for the treatment of rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for the treatment of anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Â- Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:NBIX
CUSIP64125C10
Phone858-617-7600
Employees845
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$788.10 million
Cash Flow$0.61 per share
Book Value$6.92 per share

Profitability

Net Income$37.01 million

Miscellaneous

Market Cap$9.13 billion
Next Earnings Date5/5/2021 (Confirmed)
OptionableOptionable

Headlines

Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up to $92.97
April 14, 2021 |  americanbankingnews.com
Neurocrine Biosciences (NASDAQ:NBIX) Shares Down 6%
March 30, 2021 |  americanbankingnews.com
Why Neurocrine Biosciences Stock Jumped Today
March 25, 2021 |  finance.yahoo.com
Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up to $87.57
March 25, 2021 |  americanbankingnews.com
NBIX Mar 2021 90.000 call
March 20, 2021 |  au.finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

2.29 out of 5 stars

Medical Sector

17th out of 2,024 stocks

Biological Products, Except Diagnostic Industry

2nd out of 177 stocks

Analyst Opinion: 4.3Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$96.58
+1.58 (+1.66 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

Is Neurocrine Biosciences a buy right now?

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 8 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Neurocrine Biosciences stock.
View analyst ratings for Neurocrine Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Neurocrine Biosciences?

Wall Street analysts have given Neurocrine Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Neurocrine Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Neurocrine Biosciences?

Neurocrine Biosciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 7,000,000 shares, an increase of 57.3% from the March 15th total of 4,450,000 shares. Based on an average trading volume of 1,260,000 shares, the days-to-cover ratio is currently 5.6 days.
View Neurocrine Biosciences' Short Interest
.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Neurocrine Biosciences
.

How can I listen to Neurocrine Biosciences' earnings call?

Neurocrine Biosciences will be holding an earnings conference call on Wednesday, May 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings data on Wednesday, February, 3rd. The company reported $3.58 EPS for the quarter, beating the consensus estimate of $0.59 by $2.99. The company earned $247.90 million during the quarter, compared to analyst estimates of $260.43 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 18.18% and a net margin of 8.96%.
View Neurocrine Biosciences' earnings history
.

How has Neurocrine Biosciences' stock been impacted by COVID-19?

Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NBIX shares have increased by 12.4% and is now trading at $96.58.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NBIX?

20 Wall Street analysts have issued 1-year target prices for Neurocrine Biosciences' shares. Their forecasts range from $90.00 to $163.00. On average, they expect Neurocrine Biosciences' stock price to reach $128.72 in the next year. This suggests a possible upside of 33.3% from the stock's current price.
View analysts' price targets for Neurocrine Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the following people:
  • Dr. Kevin C. Gorman, CEO & Director (Age 63, Pay $1.45M)
  • Mr. Matthew C. Abernethy, Chief Financial Officer (Age 41, Pay $822.74k)
  • Dr. Haig P. Bozigian, Chief Devel. Officer (Age 63, Pay $780.63k)
  • Mr. Eric S. Benevich, Chief Commercial Officer (Age 56, Pay $793.07k)
  • Ms. Eiry Wyn Roberts, Chief Medical Officer (Age 57, Pay $899.55k)
  • Dr. Dimitri E. Grigoriadis, Chief Research Officer (Age 63)
  • Jane Sorensen, Head of Investor Relations
  • Mr. Darin M. Lippoldt, Chief Legal Officer & Corp. Sec. (Age 55)
  • Mr. Kyle W. Gano, Chief Bus. Devel. and Strategy Officer (Age 48)
  • Ms. Julie Cooke, Chief HR Officer (Age 55)

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences CEO Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among Neurocrine Biosciences' employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Neurocrine Biosciences' key competitors?

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), The Walt Disney (DIS), Tesla (TSLA), Square (SQ) and salesforce.com (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.22%), Retirement Systems of Alabama (0.13%), DnB Asset Management AS (0.13%), State of Alaska Department of Revenue (0.06%), Cardan Capital Partners LLC (0.03%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own Neurocrine Biosciences stock include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy and Stephen A Sherwin.
View institutional ownership trends for Neurocrine Biosciences
.

Which major investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., and Pacer Advisors Inc.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Malcolm Lloyd-Smith, Matt Abernethy, and Stephen A Sherwin.
View insider buying and selling activity for Neurocrine Biosciences
or view top insider-selling stocks.

Which major investors are buying Neurocrine Biosciences stock?

NBIX stock was purchased by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, DnB Asset Management AS, Cardan Capital Partners LLC, Louisiana State Employees Retirement System, Harbour Capital Advisors LLC, State of Alaska Department of Revenue, YorkBridge Wealth Partners LLC, and FDx Advisors Inc..
View insider buying and selling activity for Neurocrine Biosciences
or or view top insider-buying stocks.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $96.58.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences has a market capitalization of $9.13 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

Neurocrine Biosciences employs 845 workers across the globe.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is www.neurocrine.com.

Where are Neurocrine Biosciences' headquarters?

Neurocrine Biosciences is headquartered at 12780 EL CAMINO REAL, SAN DIEGO CA, 92130.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.